Genenta Science S.p.A. (NASDAQ:GNTA) Short Interest Up 30.8% in January

Genenta Science S.p.A. (NASDAQ:GNTA) was the target of a large growth in short interest in January. As of January 31st, there was short interest totalling 3,400 shares, a growth of 30.8% from the January 15th total of 2,600 shares. Based on an average daily volume of 10,600 shares, the days-to-cover ratio is currently 0.3 days.

Genenta Science Price Performance

NASDAQ:GNTA traded up $0.55 during midday trading on Friday, hitting $4.37. 6,022 shares of the company were exchanged, compared to its average volume of 10,297. The company has a fifty day simple moving average of $4.46 and a 200 day simple moving average of $4.59. Genenta Science has a fifty-two week low of $2.20 and a fifty-two week high of $7.28.

Institutional Investors Weigh In On Genenta Science

A hedge fund recently bought a new stake in Genenta Science stock. Allianz SE purchased a new position in shares of Genenta Science S.p.A. (NASDAQ:GNTA) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 103,250 shares of the company’s stock, valued at approximately $444,000. Allianz SE owned approximately 0.56% of Genenta Science at the end of the most recent reporting period. Institutional investors own 15.13% of the company’s stock.

About Genenta Science

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.